首页> 外文期刊>Current drug targets-The International journal for timely in-depth reviews on drug targets >Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors
【24h】

Phosphonate Emerging Zinc Binding Group in Matrix Metalloproteinase Inhibitors

机译:基质金属蛋白酶抑制剂中的膦酸酯新兴锌结合基团

获取原文
获取原文并翻译 | 示例
获取外文期刊封面目录资料

摘要

Matrix metalloproteinases (MMPs) are zinc-dependent endopeptidases, capable to degrade the extracellular matrix (ECM) in physiologic conditions. Because of their overexpression and pivotal role in many pathological events, they have been proposed as a therapeutic and prognostic target for a number of diseases. Selectivity among MMPs is essential for realizing the clinical potential of inhibitors. The design of MMP inhibitors (MMPIs) has largely focused on development of various compounds containing a zinc binding group (ZBG) in their structure, with hydroxamate being the most potent one. Due to the high degree of homology in the catalytic domain of all the MMPs, the specificity and selectivity of first generation hydroxamate MMPIs were minimal, with several off-target effects and binding to other metzincins. This review highlights the role of phosphonate as ZBG in the design and development of new MMPIs.
机译:基质金属蛋白酶(MMP)是锌依赖性内肽酶,能够在生理条件下降解细胞外基质(ECM)。由于它们在许多病理事件中的过表达和关键作用,它们已被提议作为许多疾病的治疗和预后靶标。 MMP之间的选择性对于实现抑制剂的临床潜力至关重要。 MMP抑制剂(MMPIs)的设计主要集中于开发结构中含有锌结合基(ZBG)的各种化合物,其中异羟肟酸酯是最有效的化合物。由于所有MMP的催化域均具有高度的同源性,因此第一代异羟肟酸酯MMPI的特异性和选择性极低,具有脱靶作用,并与其他甲氧新锌结合。这篇评论强调了膦酸酯作为ZBG在新MMPI的设计和开发中的作用。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号